Barclays analyst Peter Lawson maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) yesterday and set a price target of $35.00. The company’s shares closed yesterday at $16.41.
Lawson covers the Healthcare sector, focusing on stocks such as Arcus Biosciences, Exelixis, and Iovance Biotherapeutics. According to TipRanks, Lawson has an average return of 10.0% and a 45.86% success rate on recommended stocks.
Arcus Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $41.00, implying a 149.85% upside from current levels. In a report released on February 9, Mizuho Securities also initiated coverage with a Buy rating on the stock with a $42.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $25.47 and a one-year low of $12.95. Currently, Arcus Biosciences has an average volume of 826.2K.
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RCUS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcus Biosciences (RCUS) Company Description:
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Read More on RCUS:
